The hospital involved responded in detail: "The 1-year-old child spent 550,000 yuan in hospital for four days."
CCTV News (Reporter Wang Jiazhu) A one-year-old girl spent 550,000 in the hospital for 4 days. What disease would cost so much?
Recently, a bill for hospitalization in the Pediatric Neurorehabilitation Ward of the Second Affiliated Hospital of Xi'an Jiaotong University was spread online.
According to the bill, a 1-year-old girl who was admitted to the pediatrics department of the hospital began to be hospitalized on August 17 and was discharged on August 21. The total cost of 4 days was 553639.2 yuan. Some netizens questioned the hospital’s high fees for "harvesting" patients, saying " What kind of spending money is this, it is simply a flood."
The hospitalization bill uploaded in the video shows that in the past four days, the hospital charged a bed fee of 620 yuan, a laboratory test fee of 930 yuan, a nursing fee of 80 yuan, an examination fee of 1,555 yuan, and a medical examination fee of 120 yuan. The most expensive is the western medicine fee, which is as high as 550177.2. Yuan.
The bill also showed that the overall payment for the treatment and medical insurance was 570.25 yuan, and the personal payment was 553,068.95 yuan.
At noon on September 4, the reporter contacted the Second Affiliated Hospital of Xi’an Jiaotong University. The hospital confirmed to the reporter that the above-mentioned patient was a little girl under the age of 2 who came to the Children’s Hospital of the hospital 2 months ago due to weakness in her limbs and backward movement. After seeking medical treatment, it was finally diagnosed as spinal muscular atrophy (SMA), which is a rare genetic disease.
Professor Huang Shaoping, chief expert of the Children's SMA Diagnosis and Treatment Center of the Second Affiliated Hospital of Xi'an Jiaotong University and the subject leader of the children's treatment team, introduced that spinal muscular atrophy is a disease with a very high fatal and disabling rate, with an incidence of about 1 in 10,000. If not actively treated, multi-system functional damage will gradually occur, and respiratory failure will eventually occur, and life may end at any time.
If there is no targeted therapy, you can only let it go, which means that 70%-80% of patients with type 1 SMA will die before the age of two, and patients with type 2 SMA can only sit in a wheelchair after the age of 5 or 6.
The medicine used is imported, and the metering of the medicine is prescribed by foreign researchers in the instructions. The Children's SMA Diagnosis and Treatment Center of the Second Affiliated Hospital of Xi'an Jiaotong University does not have the right to choose, and must be used in accordance with the metering prescribed by foreign countries.
Professor Huang Shaoping introduced that the import price of Nosina Raw Sodium is nationally unified, and it is now 550,000 yuan.
And in terms of drug use, public hospitals implement "zero drug addition".
It is understood that in May 2018, spinal muscular atrophy was included in the "First List of Rare Diseases" jointly formulated by the National Health Commission and other departments, and it is the second-ranked neuromuscular rare disease.
Children with onset in infancy have a high probability of not living to 2 years old.
Therefore, SMA is also known as the "number one killer of genetic diseases" for infants under 2 years of age.
Diagnosis and treatment requires comprehensive management and evaluation in multiple disciplines such as children's neurology, respiratory, orthopedics/spine, rehabilitation, and clinical nutrition to maximize the quality of life of patients.
The Propaganda Department of the Party Committee of the Second Affiliated Hospital of Xi'an Jiaotong University introduced to reporters that the Children's Hospital of the hospital is the only children's SMA diagnosis and treatment center in Northwest China. In the face of the above-mentioned infant patients who have been diagnosed, the neurological professional team of the Children's Hospital has formulated a detailed treatment plan.
According to the patient’s clinical manifestations and genetic examination results, and according to the "Clinical Practice Guidelines for Spinal Muscular Atrophy" published by the Chinese Medical Association Genetic Diseases Clinical Practice Guidelines Writing Group, the patient has no contraindications to drug use, so after communicating with parents, He also signed an informed consent to treat the patient with Noxinarine Sodium.
Nosinagen Sodium is the world's first precise targeted treatment of SMA. By increasing the level of SMN protein in patients with SMA, it can change the course of the disease and improve the prognosis.
This drug was developed by the United States to treat a rare disease of spinal muscular atrophy. It was introduced to the country by the National Medical Products Administration in February 2019. The price at that time was 700,000 yuan. This price was not reduced to January this year. 550,000.
The reporter noticed that Shandong Qilu Evening News reported a similar case in mid-March this year.
On March 3, at the Qilu Children's Hospital of Shandong University, an 18-month-old SMA patient was injected with a 5ml injection of Noxinagen sodium, which was also worth 550,000.
Professor Yang Lin, deputy director of the Department of Pediatric Internal Medicine of the Second Affiliated Hospital of Xi’an Jiaotong University and an expert on pediatric neurological diseases, reminded parents that the most typical manifestation of children with SMA is motor development retardation, that is, the child’s normal motor development is vertical head, turning over, sitting, climbing, standing, and walking. It's a process, but this kind of child can be found to be very soft in the whole body from the early stage.
If the parent finds that the child’s headrest is particularly soft by three months, the limbs are relatively less active, but the intelligence, pronunciation, and eye expression are the same as normal children, and the motor development is significantly behind and soft compared to children of the same age. This is the most common Performance.
In addition, to identify whether the child is soft or not, you can let the child lie on the parent's arm. If it is difficult to raise the head and kick up the limbs if it is built like an arch bridge, this is the easiest way to check. Head drooping and leg drooping can help identify.